Business Description
AnGes Inc
ISIN : JP3127700007
Description
AnGes Inc is a biopharmaceutical company. The company's development projects include - HGF plasmid, NFkB decoy oligonucleotide, and Therapeutic vaccine.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.43 | |||||
| Equity-to-Asset | 0.92 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 1.67 | |||||
| Beneish M-Score | -2.81 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 34 | |||||
| 3-Year EBITDA Growth Rate | -10 | |||||
| 3-Year EPS without NRI Growth Rate | 15.6 | |||||
| 3-Year FCF Growth Rate | -22.3 | |||||
| 3-Year Book Growth Rate | -18.8 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 72.5 | |||||
| 9-Day RSI | 51.5 | |||||
| 14-Day RSI | 48.2 | |||||
| 6-1 Month Momentum % | 42.2 | |||||
| 12-1 Month Momentum % | -8.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.86 | |||||
| Quick Ratio | 1.19 | |||||
| Cash Ratio | 0.94 | |||||
| Days Inventory | 1752.39 | |||||
| Days Sales Outstanding | 52.98 | |||||
| Days Payable | 494.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.3 | |||||
| Shareholder Yield % | 4.63 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 37.08 | |||||
| Operating Margin % | -1877.88 | |||||
| Net Margin % | -1876.83 | |||||
| FCF Margin % | -1771.17 | |||||
| ROE % | -36.71 | |||||
| ROA % | -31.35 | |||||
| ROIC % | -35.23 | |||||
| ROC (Joel Greenblatt) % | -1027.99 | |||||
| ROCE % | -35.92 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 21.28 | |||||
| PB Ratio | 0.48 | |||||
| Price-to-Tangible-Book | 4.87 | |||||
| EV-to-EBIT | -1.12 | |||||
| EV-to-EBITDA | -1.12 | |||||
| EV-to-Revenue | 21.1 | |||||
| EV-to-FCF | -1.25 | |||||
| Price-to-Median-PS-Value | 0.22 | |||||
| Price-to-Net-Current-Asset-Value | 8.86 | |||||
| Earnings Yield (Greenblatt) % | -89.29 | |||||
| FCF Yield % | -70.69 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
AnGes Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 3.177 | ||
| EPS (TTM) (€) | -0.286 | ||
| Beta | 0.5 | ||
| Volatility % | 97.8 | ||
| 14-Day RSI | 48.2 | ||
| 14-Day ATR (€) | 0.007769 | ||
| 20-Day SMA (€) | 0.2632 | ||
| 12-1 Month Momentum % | -8.82 | ||
| 52-Week Range (€) | 0.188 - 0.54 | ||
| Shares Outstanding (Mil) | 240.37 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AnGes Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AnGes Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
AnGes Inc Frequently Asked Questions
What is AnGes Inc(FRA:AJW)'s stock price today?
The current price of FRA:AJW is €0.26. The 52 week high of FRA:AJW is €0.54 and 52 week low is €0.19.
When is next earnings date of AnGes Inc(FRA:AJW)?
The next earnings date of AnGes Inc(FRA:AJW) is .
Does AnGes Inc(FRA:AJW) pay dividends? If so, how much?
AnGes Inc(FRA:AJW) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers